Location & dates EMBL Heidelberg, Germany 9 - 12 Mar 2020
Deadlines Application closed
organiser_roche

Coronavirus information for participants

The onsite course and conference programme at EMBL has been paused until the end of June 2020.


We aim to continue offering our advanced training for the scientific community however we safely can. While some events have been cancelled, many have been rescheduled for a later date and others will be delivered as virtual events.


Registration is open for onsite courses and conferences starting after 1 July and for the virtual events. All registration fees for any events which don’t take place due to the COVID-19 disruption are fully refundable.


More information for participants of events at EMBL Heidelberg can be found here.

EMBL has taken the difficult decision to pause our programme of external courses and conferences. As a result, we are cancelling the course and apologise for the inconvenience. 

Course Overview

Minimally invasive liquid biopsies have recently emerged as novel diagnostic methods which hold the promise to monitor disease progression, detect minimal residual disease, therapy resistance and potentially even early cancer detection. Participants will gain hands-on experience in the detection of cell free tumor DNA (cfDNA) using a next generation sequencing (NGS) approach that covers all four mutation classes in a single assay. Critical aspects on recent developments to increase analytical sensitivity and mitigate sequencing errors (computational error correction) will be discussed as well as annotation, interpretation, and clinical reporting of liquid biopsy tests. Lectures will cover the evaluation of ctDNA as biomarkers, clinical applications, emerging analytes for liquid biopsy and important challenges.

Audience

The course is aimed at scientists, clinical scientists, molecular pathologists and industry researchers who would like to learn about possible applications and want to gain hands-on experience in the field of liquid biopsy from sample acquisition, target enrichment, analysis and interpretation.

Modules/Resources

  • Possible use cases of nucleic acids in blood and plasma in clinical settings
  • Strategies for the construction of high quality NGS libraries from challenging cfDNA samples (sample and molecular barcoding, low input amounts, quality controls)
  • In-solution hybridization based target enrichment of clinically relevant targets, covering all four mutation classes in a single assay (SNVs, fusions, indels, CNVs)
  • Bioinformatics analysis including integrated digital error suppression (iDES), variant calling and reporting
  • Annotation, interpretation of mutations and clinical reporting (therapy matching and optional clinical decision support)

Learning Outcomes

  • Understanding of potential applications for liquid biopsy in clinical care
  • Challenges that must be overcome before liquid biopsies can be applied in precision medicine
  • Overview of emerging liquid biopsy methods and markers
  • Ability to handle cfDNA, generate NGS libraries, enrich targets of interest, annotate and interprate of variants and their frequences

 

EMBL Courses and Conferences are kindly supported by our Corporate Partnership Programme

Founder partners

  • Leica logo
  • Olympus logo

Corporate partners

  • 10x Genomics_120x82
  • Becton Dickinson logo
  • Bio-Rad logo
  • Boehringer Ingelheim logo
  • Eppendorf logo
  • GSK logo
  • Milteniy Biotec logo
  • Stilla logo
  • ThermoFisher logo

Associate partners

  • Merck logo
  • New England Biolabs logo
  • Nikon logo
  • Promega logo
  • Roche logo
  • Sanofi logo
  • Sartorius logo